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The monoclonal antibody field is a rapidly growing biotechnology. 
antibodies have been hailed by many as the perfect medical weapon, the magic 
bullet, that will be effective against several human diseases, including 
cancer. 
such as bacteria or viruses. In the past it has not been feasible to treat 
patients with antibodies taken from the blood of immune individuals because 
of a lack of suitable donors and the expense of separating the antibodies 
from other blood components. There is also the risk that some patients will 
react adversely to these preparations. 
Monoclonal 
Antibodies are produced by the body to defend against foreign agents 
Laboratory production of large quantities of monoclonal antibodies can be 
achieved by hybrid cells called hybridomas. Hybridomas are made by fusing 
specific antibody producing lymphocytes with laboratory-grown tumor cel Is, 
the result of which are cells that have characteristics of both parents. 
The ability to grow forever comes from the tumor cell--to produce antibody 
comes from the lymphocyte cell. This technology will allow pharmaceutical 
companies to make them available to patients. 
Although this market is projected to be two billion dollars in diagnostics 
alone by the end of this decade, the technology has not kept up with demand. 
According to a recent article in the Wall Street Journal, some projects have 
made it to the market place, but in general, techniques need to be developed 
to overcome some o f  the technical problems. Most hybridoma production to 
date has been in the mouse system. 
has become almost routine, but the same techniques applied to human cells 
have not resulted in the consistent production of desirable hybridomas. 
Production of hybridomas from mouse cells 
In our experience there are essentially five critical steps for producing 
human hybridomas. 
specific antibody desired; (2) separation of specific-producing cells from 
nonproducers; (3) fusion of desired cells with tumor cells by membrane 
interactions; (4) maintaining sustained production of antibody for months; 
and (5) separation and concentration of antibody from the cell culture 
medium. 
community, that hybridoma technology is still evolving and significant 
improvements are needed to increase the efficiency of the steps listed 
These are: (1) stimulation of lymphocytes to produce the 
It is our impression, and one held by others in the scientific 
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before we can realize our objective of mass producing monoclonal anti- 
bodies for the treatment of diseases. 
Research is needed to define more completely the environmental conditions 
that must be met in order to successfully produce human hybrid cells. We 
believe the bioreactor being developed at NASA will enable us: (1) to deter- 
mine the optimal conditions (e.g., pH, O, CO,, nutrients) for growth of hy- 
bridoma cells, and (2) to determine whether cell growth and antibody produc- 
tion are enhanced in the microgravity o f  space. 
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